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No evidence to support the use of fibrin glue following
Pancreaticoduodenectomy
Post operative pancreatic fistula (POPF) remains a significant source of morbidity for patients undergo-
ing pancreaticoduodenectomy. Martin and Au performed a randomised trial to answer the question
whether the use of fibrin glue could reduce the incidence of POPF. Although a previous large RCT of
patients undergoing pancreatic surgery with ‘high risk’ pancreatic remnants showed no difference in
POPF, the authors argue differences in the methodology of the current trial add to the literature on this
subject. Two significant points of difference were the use of fibrin glue to all anastomoses following
pancreaticoduodenectomy and the use of drain lipase at post operative day 3 to define pancreatic fistula.
The trial showed no difference in POPF rates (~40% in each arm) and no differences in non-pancreatic
anastomotic leak rates. The authors conclude that fibrin glue does not reduce rates of anastomotic leak
but also that elevated drain lipase does not predict an altered clinical course. It is important to consider
the conduct of any RCT. Randomisation was by coin toss and uneven numbers between the two groups
resulted. There was no stratification or limitation of the trial to patients with a ‘high risk’ pancreatic
remnant and power calculations were based on 5 fold reduction in the POPF rate (40% to 8%).Was this
reduction a realistic expectation when previous trials have not shown such reductions in fistula rates? If
not, then the trial was likely to be predetermined to show no difference. The choice of drain lipase at day
3 is also interesting as drain amylase has traditionally been the standard assessment. The authors note the
lack of data on lipase levels from which to base their power calculations but perhaps more importantly is
the timing of the measurement. Drain amylase levels have previously been shown only to correlate with
POPF if measured early within 24 hours and by day 3 are not predictive of POPF. Whether the same
applies to lipase levels cannot be elucidated from the current trial. Despite these issues, this trial further
supports the notion that fibrin glue is not the answer to preventing POPF.
Saxon Connor
High intensity focused ultrasound — a big hitter with low impact?
High-intensity focused ultrasound (HIFU) as a technology has been around for a while but with limited
availability and application in humanmedicine. The technique focuses a particular frequency of ultrasound
waves within tissues very accurately and the oscillation of molecules at the point of focus produces heat
creating a thermal burn. Cheung and colleagues from Hong Kong have used HIFU to target small (<3 cm)
hepatocellular carcinomas (HCC) in a group of 47 patients. They compared their outcomes with a group of
59patientswhounderwent radiofrequency ablationduring the same timeperiod.Accepting that thiswas not
a randomizedcontrolled trial and that theremay thereforebe someselectionbias,HIFUperformedextremely
well with good ablation rates and comparable if not better survival than RFA treated patients. In addition
more than half of the patients in this study had failed the screening criteria for radiofrequency ablation due
to poor tumour visualization or technical difficultiesmaking this an important indication.Thismay prove to
be a very valuable tool for patients who don’t want surgery or who are at risk of decompensating from
underlying liver disease or who may require major surgery such as liver transplantation in the future.
Stephen Wigmore
Risk Management
Neoadjuvant chemoradiotherapy (NARx) benefits some patients with advanced pancreatic cancer (PCa).
Its value includes maximizing multimodality therapy for more patients, reducing lymph nodemetastases,
and promoting tumor regression. It is combined typically with today’s aggressive surgical approaches for
clinically responsive patients with initially unresectable (Un-R) or borderline resectable (B-R) disease.
After months of systemic chemotherapy and targeted radiation, the patient and surgeon will enter the
operating theatre, but at what, if any, additional risk? Araujo et al. fromMemorial Sloan Kettering Cancer
Center compared outcomes between 29 Un-R and B-R patients whose tumors were resected after NARx
with 29 resectable PCa patients who received no NARx. They used a case-matched study design to
neutralize confounding clinical variables. Between these two patient groups derived over 10 years, rates of
overall post-operative complications,major complications, pancreatic fistulae andmortality were similar.
Were the operations after NARx more difficult? Probably, but blood loss amounts, transfusions and
operative times were statistically similar as were the rates (14% in each group) of vascular resection.
Pathological data (T and N stage) clearly favored NARx patients, suggesting a local treatment effect that,
after all, made resection even possible. The study has several limitations of course including a 5% actual
down-staging rate and variances to those NARx regimens being tested today (folfirinox, Cyberknife).
Nonetheless, the results suggest that qualified surgical teams can manage safely properly selected patients
across inherent risks to potential benefit.
Mark Callery
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